Infographic : Brooks Labrotories (NSE : BROOKS) | Q2 Results Released! | Revenue DOWN 15.74% YoY

Brooks Laboratories Ltd is a pharmaceutical contract manufacturing company. The company has manufacturing facilities in Baddi Himachal Pradesh and Vadodara Gujarat. Both units are cGMP compliant in accordance with national and international standards.

The Vadodara facility has been approved by the European Medicines Agency. The company has a wide range of products for the critical care segment in the parenteral section such as Beta Lactam Cephalosporin and generic dry powder injection ampoules and liquid vials Dry syrups and tablets etc.

Their product portfolio currently includes 28 injectables 19 tablets and 2 dry syrups that are sold on the domestic market. The company’s manufacturing facilities are designed to manufacture various products in the formula segment using a combination of processes. V Baddi manufactures a wide range of products in the formulation segment for various top companies in India.

The company’s total revenue on a consolidated basis for the quater ended September 30, 2022 stood at Rs 18.2 Crore, an decrease of 15.74 % over the previous year. The company’s operating expenses on a consolidated basis for the quater ended September 30, 2022 stood at Rs 27.3 Crore, an increase of 6.64 % over the Previous Year.

Loss before tax is Rs 12 Crore, an increase of 84.61 % over the previous year. EPS on a consolidated basis for the quater ended September 30, 2022 stood at Rs 3.2, an decrease of 60.00 % over the Previous Year.